SWTX - SpringWorks Therapeutics, Inc.
| Previous Close | 27.50 |
| Open | 27.47 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 800 |
| Day's Range | 27.47 - 30.30 |
| 52 Week Range | 17.02 - 30.42 |
| Volume | 352,785 |
| Avg. Volume | 218,270 |
| Market Cap | 1.3B |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -13.84 |
| Earnings Date | Nov 12, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 34.00 |
- GlobeNewswire
Researchers Present Preclinical Data Showing Synergistic Activity of SpringWorks Therapeutics’ Gamma Secretase Inhibitor (Nirogacestat) with GlaxoSmithKline’s BCMA Antibody-Drug Conjugate (Belantamab Mafodotin) at the American Society of Hematology (ASH) Annual Meeting
STAMFORD, Conn., Dec. 09, 2019 -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for.
- GlobeNewswire
SpringWorks Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights
– Commenced Phase 2b ReNeu Clinical Trial for Patients with Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) – – Received Important Regulatory.
- GlobeNewswire
SpringWorks Therapeutics Announces Initiation of Phase 2b ReNeu Clinical Trial of Mirdametinib in Children and Adults with Neurofibromatosis Type 1 (NF1)-Associated Plexiform Neurofibromas (NF1-PN)
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that the first patient has been dosed in the Phase 2b ReNeu clinical trial evaluating mirdametinib (formerly PD-0325901), an oral, small molecule designed to inhibit MEK1 and MEK2, in children and adult patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (NF1-PN). The disorder is characterized by mutations in the NF1 gene, which affects the MAPK pathway. Throughout their lifetime, approximately 30% to 50% of NF1 patients progress to develop plexiform neurofibromas, which are peripheral nerve sheath tumors that cause significant pain, disfigurement and morbidity.
- Barrons.com
Beacon Roofing, Sunrun, Marchex and Other 13D Filings
Velan Capital and LTE Partners disclosed jointly on Sept. 19 that they added 658,061 shares to their stake in the cancer-focused biopharmaceutical at prices of $4.39 to $4.99 each from Sept. 3 to Sept. 9. The investors now hold a total of 10,161,733 shares, equal to about 11.5% of Progenics’ outstanding stock.
- GlobeNewswire
European Commission Grants Orphan Drug Designation for Nirogacestat for the Treatment of Soft Tissue Sarcoma
SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the European Commission has granted Orphan Drug Designation for nirogacestat, an oral, selective, small molecule, gamma-secretase inhibitor, for the treatment of soft tissue sarcoma. SpringWorks is currently enrolling patients in the Phase 3 DeFi trial of nirogacestat for the treatment of adult patients with progressing desmoid tumors, which are a type of soft-tissue tumors that are often treated by sarcoma specialists. Desmoid tumors are rare and often debilitating and disfiguring, and can aggressively invade surrounding healthy tissues and cause significant morbidities, including severe pain, internal bleeding, incapacitating loss of range of motion, and, in rare cases, death.1 It is estimated that 1,000 to 1,500 new desmoid tumor patients are diagnosed each year in the United States.2,3 There are currently no therapies approved by the U.S. Food and Drug Administration (FDA) for the treatment of desmoid tumors.
- GlobeNewswire
SpringWorks Therapeutics Announces Closing Of Initial Public Offering and Exercise in Full of the Underwriter’s Option to Purchase Additional Shares
STAMFORD, Conn., Sept. 17, 2019 -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for.
- Investor's Business Daily
Cloudflare IPO Prices Above Range, Raises $525 Million
Internet services company Cloudflare was set to begin trading Friday, after raising $525 million with an initial public offering that priced Thursday. Cloudflare offered 35 million shares.
- GlobeNewswire
SpringWorks Therapeutics Announces Pricing Of Initial Public Offering
SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the pricing of its initial public offering of 9,000,000 shares of its common stock at a price to the public of $18.00 per share. All of the shares are being offered by SpringWorks. The gross proceeds to SpringWorks from the offering, before deducting underwriting discounts and commissions and estimated offering expenses to be payable by SpringWorks, are expected to be $162 million.
